Clinical trial
A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With…
NCT02386553 · Biogen, Industry · Completed
Key facts
| NCT number | NCT02386553 |
|---|---|
| Title | A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy |
| Official title | An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy |
| Acronym | NURTURE |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Spinal Muscular Atrophy |
| Intervention type | Drug |
| Interventions | Nusinersen |
| Enrollment | 25 |
| Start date | May 18, 2015 |
| Primary completion | Dec 17, 2024 |
| Completion | Dec 17, 2024 |
| First posted | Mar 12, 2015 |
| Last update posted | Oct 20, 2025 |
| Countries | Australia, Germany, Italy, Qatar, Taiwan, Turkey (Türkiye), United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: